New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session

Boehringer Ingelheim has today announced that new findings from ongoing Pradaxa® (dabigatran etexilate) research will be presented during the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14) in Washington, USA, 29 – 31 March 2014. The data form part of Boehringer Ingelheim’s ongoing commitment to scientific innovation and advancing patient care.

Data from three separate company-sponsored Pradaxa®-related studies will be announced during the congress. The presentations will cover subgroup results from the pivotal RE-LY® trial, evaluating the use of Pradaxa® compared to warfarin in patients with atrial fibrillation and valvular heart disease*.¹ An oral presentation will highlight new data from pre-clinical research into an investigational antidote for Pradaxa®.² Furthermore, first data from GLORIA™-AF, one of the largest worldwide atrial fibrillation registries will be announced.³ The GLORIA™-AF registry programme is expected to provide meaningful knowledge on the global role and use of antithrombotic treatments in protecting patients with atrial fibrillation against the devastating effects of stroke.⁴

“The American College of Cardiology’s 63rd Annual Scientific Session provides a key opportunity to share new data with physicians to increase understanding of the latest developments in the field of anticoagulation,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “At Boehringer Ingelheim we are proud of our commitment to driving research and innovation in the cardiovascular area. We hope this new data will support ongoing efforts to improve patient outcomes, especially in the area of stroke prevention in atrial fibrillation.”

Details of the Pradaxa® abstracts to be presented during the American College of Cardiology’s 63rd Annual Scientific Session can be found within the Scientific Programme, available here.

Additional information about Pradaxa® will be available at the Boehringer Ingelheim booth #3227 at the American College of Cardiology’s 63rd Annual Scientific Session.

References

1. Ezekowitz M, et al. Comparison of Dabigatran versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: The RE-LY®Trial. Poster Presentation #115 at 9:30am-12:30pm EDT, Saturday 29 March 2014 in Hall C at the American College of Cardiology’s 63rd Annual Scientific Session, Washington, USA.
2. Grottke O, et al. A Specific Antidote to Dabigatran Reduces Blood Loss in Dabigatran- and Trauma-induced Bleeding in Pigs. Oral Presentation Session #921 at 10:45am EDT, Sunday 30 March 2014 in Room 145B at the American College of Cardiology’s 63rd Annual Scientific Session, Washington, USA.
3. Rothman K, et al. The Global Registry Program on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF): First Assessment of Baseline Characteristics of Dabigatran and VKA Cohorts in North America. Poster Presentation #104 at 1:30pm-4:30pm, Sunday 30 March 2014 in Hall C at the American College of Cardiology’s 63rd Annual Scientific Session, Washington, USA.
4. GLORIA-AF Registry website. https://www.gloria-af.com/public/about-objectives.html Last accessed 19 March 2014.